A new BCG treatment for bladder cancer that hasn't spread
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new form of intravesical (given directly into the bladder) treatment called rMBCG for people with non-muscle invasive bladder cancer who have not had BCG therapy before. It may be an option for those with certain types of early bladder cancer, including carcinoma in situ (CIS) or papillary tumors after removal surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have early-stage bladder cancer that hasn't spread into the bladder muscle, and you have not received BCG treatment before.
- Your cancer is either CIS (a flat, high-risk type) or papillary tumors (stage Ta or T1) after a procedure to remove visible tumors.
- You are in reasonably good health, able to care for yourself, and have adequate blood counts and liver and kidney function.
- You do not have active infections, heart failure, recent heart attack, or unstable angina.
- You are not pregnant, nursing, or using certain medications that could interfere with the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial offers early access to a new form of the BCG vaccine (a treatment that helps your immune system fight bladder cancer) for people with non-muscle invasive bladder cancer. It may be an option if the standard vaccine is not available or has not worked for you.
This trial tests a personalized approach to using BCG immunotherapy for high-risk non-muscle-invasive bladder cancer. It aims to improve treatment response by tailoring the therapy based on your immune system.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This trial tests a new combination treatment (SHR-1501 plus BCG) compared to standard chemotherapy for people with bladder cancer that hasn't responded to BCG. The goal is to see if this combination works better at controlling the cancer.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This trial tests a new drug (FL115) given directly into the bladder, alone or with BCG, for people with a type of bladder cancer that has not responded to BCG therapy. It aims to find a better treatment option for those who cannot have or refuse bladder removal surgery.
Hear when a new NMIBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.